Facebook has embraced young workers and crafted management techniques that give them unusual freedom to choose, and change, assignments.
Novartis has won approval in Japan for a new psoriasis drug, the first country to give the treatment a green light for commercialization.
U.S. watchmaker Fossil hopes $1,595 timepieces will bridge the gap between mass market and high-end.
Eight-year-old carpooling service BlaBlaCar is gaining on the back of Europe’s deteriorating public-transport and as a low-key and long-distance alternative to trains.
Google is one of many fast-growing employers eschewing suburban campuses for clusters in cities, partly in a push to foster collaboration among employees.
RadioShack has shut more stores in the past two months than the rest of the year, though it’s hard to tell the difference. The chain still has a heavy surplus of stores in many local markets.
Sock manufacturing is making a modest comeback in the U.S., helped by more efficient machines, tepid wage growth and retailers’ desire to give more shelf space to U.S.-made products.
Germany’s HeidelbergCement has agreed to sell operations in North America and the U.K. for $1.4 billion to a U.S. affiliate of Lone Star Funds.
Pharmalot: A new year always brings new challenges, and the pharmaceutical industry certainly has its share, says columnist Ed Silverman.
Many deals are running into a growing corps of global deal cops, each wanting a say over transactions that touch their industries, economies or interests.